CA1095044A - N-piperid-4-yl benzamide compounds - Google Patents
N-piperid-4-yl benzamide compoundsInfo
- Publication number
- CA1095044A CA1095044A CA289,825A CA289825A CA1095044A CA 1095044 A CA1095044 A CA 1095044A CA 289825 A CA289825 A CA 289825A CA 1095044 A CA1095044 A CA 1095044A
- Authority
- CA
- Canada
- Prior art keywords
- amino
- methoxy
- chlorobenzamide
- benzyl
- general formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
Abstract
ABSTRACT OF THE DISCLOSURE
Novel therapeutically useful piperidine derivatives of the formula:
in which the symbols denote various substitutents, are disclosed.
The compounds I exhibit the ability to antagonize the effects of dopamine or dopaminergic agents.
Novel therapeutically useful piperidine derivatives of the formula:
in which the symbols denote various substitutents, are disclosed.
The compounds I exhibit the ability to antagonize the effects of dopamine or dopaminergic agents.
Description
lO~9S044 This invention relates to new therapeutically useful piperidine derivatives, to processes for their preparation and pharmaceutical compositions containing them.
The new piperidine derivatives of the present invention are those compounds of the general formula:
Rl ~ R ~h 1 4 \~ \t6~
R R
wherein R represents an alkoxy group containing 1 to 3 carbon atoms or an allyloxy group; R represents a hydrogen atom or an amino, alkylamino contain-ing 1 to 3 carbon atoms or acylamino group containing 2 to 4 carbon atoms and wherein the alkyl group may be substituted with 1 to 3 halogen atoms; R2 re-presents a hydrogen or halogen atom or an amino, sulphamoyl or alkylsulphonyl group containing 1 to 3 carbon atoms, with the proviso that R and R do not both represent hydrogen atoms; R represents a hydrogen atom, an alkyl group containing 1 to 3 carbon atoms, or a phenyl group; R4 represents a cyclohexyl, cyclohexenyl, cyclohexadienyl or thienyl group, or a phenyl group of the general formula: R8 R
~/~~
\~Rl O
wherein R8, R9 and R10 each represents a hydrogen or halogen atom or an alkyl group containing 1 to 3 carbon atoms; R5 represents a hydrogen atom or an alkyl group containing 1 to 3 carbon atoms; R6 and R7 each represents a hydrogen atom, a benzyl group or an alkyl group containing 1 to 3 carbon atoms, with the proviso that R and R7 are not both hydrogen atoms when R5 represents a hydrogen atom; and W represents a single bond or an alkylene group containing 1 to 3 carbon atoms, or a pharmaceutically acceptable acid addition salt thereof.
Preferred compounds of general formula I are those of the more ~09S(~44 specific formula: R5' R ~ CON ~ N-CII-W'-R4' III
< `-1' R' R6, 1' [wherein R' represents a methoxy, ethoxy or allyloxy group; R represents a hydrogen atom or an amino or methylamino group, or an alkanoylamino group, e.g. acetamido or trifluoroacetamido; R represents a hydrogen, chlorine or bromine atom or an amino, sulphamoyl or methylsulphonyl group, with the proviso that R and R do not both represent hydrogen atoms; R3 represents a hydro-gen atom, or a methyl or phenyl group; R represents a cyclohexyl, cyclohex-enyl or cyclohexadienyl group, or a phenyl group optionally substituted by a halogen atom or a lower alkyl group, or R4 represents a thienyl group, R5 represents a hydrogen atom or a methyl group; R6 and R7 each represent a hydrogen atom or a methyl, ethyl or benzyl group, with the proviso that R6 and R7 are not both hydrogen ~ ~ ~ -3-109504~
atoms when R5 represents a hydrogen atom, and W' represents a methylene group or, preferably~ a single bond] and pharmaceutically-acceptable acid addition salts thereof.
Of the compounds of general formula III those wherein R' repre-sents a methoxy group~ Rl represents an amino group, R2 represents a chlorine atom, R3 represents a hydrogen atom, R4 represents the cyclo-hexyl, cyclohex-3-enyl or cyclohexa-1,4-dienyl group, or a phenyl group op-tionally substituted by a halogen atom or a lower alkyl group, R repre-sents a hydrogen atom or a methyl group, R6 and R7 each represent a hy-drogen atom or a methyl, ethyl or benzyl group with the proviso that R6and R7 are not both hydrogen atoms when R5 represents a hydrogen atom, and W' represents a single bond, are of particular importance.
Of outstanding importance are N-~l-benzyl-2,6-dimethylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide, N-~l-benzyl-3-methylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide, N-ethyl-N-~l-benzylpiperid-4-yl)-
The new piperidine derivatives of the present invention are those compounds of the general formula:
Rl ~ R ~h 1 4 \~ \t6~
R R
wherein R represents an alkoxy group containing 1 to 3 carbon atoms or an allyloxy group; R represents a hydrogen atom or an amino, alkylamino contain-ing 1 to 3 carbon atoms or acylamino group containing 2 to 4 carbon atoms and wherein the alkyl group may be substituted with 1 to 3 halogen atoms; R2 re-presents a hydrogen or halogen atom or an amino, sulphamoyl or alkylsulphonyl group containing 1 to 3 carbon atoms, with the proviso that R and R do not both represent hydrogen atoms; R represents a hydrogen atom, an alkyl group containing 1 to 3 carbon atoms, or a phenyl group; R4 represents a cyclohexyl, cyclohexenyl, cyclohexadienyl or thienyl group, or a phenyl group of the general formula: R8 R
~/~~
\~Rl O
wherein R8, R9 and R10 each represents a hydrogen or halogen atom or an alkyl group containing 1 to 3 carbon atoms; R5 represents a hydrogen atom or an alkyl group containing 1 to 3 carbon atoms; R6 and R7 each represents a hydrogen atom, a benzyl group or an alkyl group containing 1 to 3 carbon atoms, with the proviso that R and R7 are not both hydrogen atoms when R5 represents a hydrogen atom; and W represents a single bond or an alkylene group containing 1 to 3 carbon atoms, or a pharmaceutically acceptable acid addition salt thereof.
Preferred compounds of general formula I are those of the more ~09S(~44 specific formula: R5' R ~ CON ~ N-CII-W'-R4' III
< `-1' R' R6, 1' [wherein R' represents a methoxy, ethoxy or allyloxy group; R represents a hydrogen atom or an amino or methylamino group, or an alkanoylamino group, e.g. acetamido or trifluoroacetamido; R represents a hydrogen, chlorine or bromine atom or an amino, sulphamoyl or methylsulphonyl group, with the proviso that R and R do not both represent hydrogen atoms; R3 represents a hydro-gen atom, or a methyl or phenyl group; R represents a cyclohexyl, cyclohex-enyl or cyclohexadienyl group, or a phenyl group optionally substituted by a halogen atom or a lower alkyl group, or R4 represents a thienyl group, R5 represents a hydrogen atom or a methyl group; R6 and R7 each represent a hydrogen atom or a methyl, ethyl or benzyl group, with the proviso that R6 and R7 are not both hydrogen ~ ~ ~ -3-109504~
atoms when R5 represents a hydrogen atom, and W' represents a methylene group or, preferably~ a single bond] and pharmaceutically-acceptable acid addition salts thereof.
Of the compounds of general formula III those wherein R' repre-sents a methoxy group~ Rl represents an amino group, R2 represents a chlorine atom, R3 represents a hydrogen atom, R4 represents the cyclo-hexyl, cyclohex-3-enyl or cyclohexa-1,4-dienyl group, or a phenyl group op-tionally substituted by a halogen atom or a lower alkyl group, R repre-sents a hydrogen atom or a methyl group, R6 and R7 each represent a hy-drogen atom or a methyl, ethyl or benzyl group with the proviso that R6and R7 are not both hydrogen atoms when R5 represents a hydrogen atom, and W' represents a single bond, are of particular importance.
Of outstanding importance are N-~l-benzyl-2,6-dimethylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide, N-~l-benzyl-3-methylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide, N-ethyl-N-~l-benzylpiperid-4-yl)-
2-methoxy-4-amino-5-chlorobenzamide and N-~l-cyclohexylmethyl-3-methylpi-perid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide, and their pharmaceutically-acceptable acid additon salts.
According to a feature of the present invention, the compounds of general formula I are prepared by the process which comprises reacting a reactive derivative of a benzoic acid of the general formula:
Rl ~ ; C00~l IV
~wherein R, Rl and R2 are as hereinbefore defined) with a piperidine deri-vative of the general formula:
HN --~N-CH-W-R V
wherein the various symbols are as hereinbefore defined. The reactive deri-vative of the said benzoic acid may be a halide (preferably chloride), an alkyl ester (preferably methyl ester), an anhydride or a mixed anhydride.
The reaction is preferably carried out in the presence of an inert organic solvent, for example ethyl methyl ketone, benzene, toluene, chloro-form, tetrahydrofuran, N,N-dimethylformamide or dioxan, at a temperature between -5 and 120C.
Halides of the benzoic acids of general formula IV can be prepared 10 by reaction of the acid with thionyl chloride or a phosphorus halide in the presence of an inert organic solvent such as benzene, toluene or a haloge-nated hydrocarbon. Mixed anhydrides of the benzoic acids of general formula IV can be prepared by the reaction of the acid with, for example, an alkyl chloroformate in the presence of an organic nitrogen-containing base, e.g.
triethylamine, in an inert organic solvent, e.g. tetrahydrofuran, methylene chloride or N,N-dimethylformamide, and at a temperature between -20 and +25C. Esters and anhydrides of the benzoic acids of formula IV, which may be employed as starting materials in the aforementioned process, can be prepared from the benzoic acids by methods known per se.
The piperidine derivatives of general formula V wherein R7 is a hydrogen atom can be prepared by reduction of corresponding 4-piperidone oximes with lithium aluminium hydride in the presence of diethyl ether or tetrahydrofuran, or by reductive amination of corresponding 4-piperidones dissolved in an organic solvent, e.g. an alcohol containing 1 to 4 carbon atGms, in the presence of platinum or Raney nickel as catalyst. The piper~-~ dine derivatives of general formula V wherein R is a cyclohexadienyl group . _ ~
. ,, ~S0~4 can be prepared from the corresponding compounds of general formula V where-in R~ is a phenyl group by reduction with lithium in liquid ammonia or a lower alkylamine. The piperidine derivatives of general formula V wherein R is a lower alkyl or benzyl group can be prepared from corresponding N-acyl substituted compounds by reduction of the carbonyl group therein to methylene using lithium aluminium hydride. Other piperidine derivatives of general formula V can be prepared by methods known ~ se.
The piperidine derivatives of general formula I are also prepared, according to a further feature of the invention, by the direct reaction of a benzoic acid of general formula IV with a piperidine derivative of general formula V in the presence of an appropriate dehydrating agent. Such agents are silicon tetrachloride, a mono-, di- or trialkyl-silyl chloride, titanium tetrachloride, N,N'-dicyclohexyl-carbodiimide, thionyl chloride, sulphur trioxide in dimethyl sulphoxide, toluene-~-sulphonyl chloride, acetone dim-ethyl acetal or a polymeric dehydrating agent. The reaction is carried out in an inert organic solvent, e.g. methylene chloride, ace~one, pyridine, ethyl acetate or dioxan, at a temperature between 20 and 110C.
In the preparation of those compounds of general formula I, where-in the symbol(s) Rl and/or R2 represent(s) an amino group, by the aforemen-tioned processes it is sometimes advisable to use as starting material cor-responding compounds in which the amino group is protected by an acyl group, the acyl protecting group preferably being acetyl, chloroacetyl, trifluoro-acetyl or phthaloyl. After the reaction the N-acylated intermediate products are subjected to acid or alkaline hydrolysis to give the corresponding com-pound of general formula I in which Rl and/or R2 represent~s) an amino group.
Acid hydrolysis of the N-acylated intermediate compounds may be carried out by heating with dilute hydrochloric acid, preferably at the boiling point of the reaction mixture, while alkaline hydrolysis is preferably carried out at a temperature between 20 and 90C with sodium or potassium hydroxide in an aqueous-alcoholic solution.
1~95(1 44 The piperidine derivatives of general formula I have as their principal pharmacological properties the ability to antagonise the effects of dopamine or dopaminergic agents of endogenous or exogenous origin and to cause stimulation of serotoninergic mechanisms. In those circumstances where hemeostatic control is a balance between dopaminergic and serotoniner-gic mechanisms these two actions are synergistic and the precise contribu-tion of each one to the final biological response is difficult to determine.
As a group they have exhibited activities which may be considered beneficial in the treatment of obesity and a variety of gastrointestinal and cerebral malfunctions in mammals, including man. Their characteristic properties in experimental animals are antagonism of the effects of dopaminergic agents such as apomorphine, induction of catatonia, production of local anaesthesia, stimulation of gastrointestinal transit and induction of both spasmogenic and spasmolytic effects on smooth muscle according to the initial resting tone. Nevertheless, as within the series antidopaminergic, serotoninergic and local anaesthetic potency do not necessarily run in parallel, the clini-cal applications of the various derivatives may well be different. As a group, they may be useful as anorectic drugs in the treatment of obesity, and be effective in the treatment of nausea and vomiting of diverse origin such as that resulting from gastrointestinal disorders, congestive heart failure, post-operative conditions etc., as well as in the treatment of other gastrointestinal disorders such as dyspepsia, flatulance, bile regurgi-tation, hiatus nernia, peptic ulcer, reflux oesophagitis, gastritis, duode- `
nitis and cholelithiasis. They may also be useful in the treatment of a variety of conditions affecting the central nervous system such as acute and chronic psychosis, manic psychosis, schizophrenias, serious disturbances of behaviour and non-melancholic depressive states and migraine. Useful anorectic and antiemetic dosages of the more interesting compounds appear to lie between 5 and 100 mg. per day.
For therapeutic purposes the compounds of general formula I may be l~S044 employed in the form of biologically and pharmacologically-acceptable in-organic or organic acid addition salts such as sulphates, hydrohalides (e.g.
hydrochlorides), phosphates, lower alkanesulphonates, arylsulphonates, and salts of aliphatic or aromatic acids containing from 1 to 20 carbon atoms which may contain one or more dou~le bonds, or other functional groups such as hydroxy, lower alkoxy, amino or keto, e.g. fumarates.
They may also be used in the form of pharmacologically-acceptable quaternary ammonium salts such as those salts formed by reaction of the com-pounds of general formula I with lower alkyl halides (e.g. methyl iodide) or sulphates, or in the form of oxygenated derivatives in which oxygen is attached to the nitrogen atom of the piperidine nucleus, viz. the N-oxides.
The pharmacologically-acceptable acid addition salts, quaternary ammonium salts and N-oxides of the compounds of general formula I may be prepared by methods known per se.
Also included within the scope of the present invention are phar-maceutical compositions which comprise, as active ingredient, at least one compound of general formula I, or a pharmacologically-acceptable acid addi-tion or quaternary ammonium salt thereof or N-oxide thereof, in association with a pharmaceutically-acceptable carrier or diluent. Preferably the com-positions are made up in a form suitable for oral, topical, percutaneous orparenteral administration.
The pharmaceutically-acceptable carriers or diluents which are ad-mixed with the active compound) or compounds, or salts or N-oxides of such compounds, to form the compositions of this invention are well known ~ se and the actual excipients used depend inter alia on the intended method of administering the compositions. Compositions of this invention are prefer-ably adapted for administration ~ os. In this case, the compositions for oral adminstration may take the form of tablets, capsules, lozenges or effer-vescent granules or liquid preparations, such as mixtures, elixirs, syrups or suspensions, all containing one or more compounds of the invention; such lO9S~44 preparations may be made by methods well known in the art.
The diluents which may be used in the preparation of the composi-tions include those liquid and solid diluents which are compatible with the active ingredient, together with colouring or flavouring agents, if desired~
Tablets or capsules may conveniently contain between 1 and 200 mg, and pre-ferably from 2 to 100 mg, of active ingredient or the e~uivalent amount of an acid addition salt, quaternary ammonium derivative or N-oxide thereof.
The liquid compositions adapted for oral use may be in the form of solutions or suspensions. The solutions may be aqueous solutions of a soluble salt or other derivative of the active compound in association with, for example, sucrose to form a syrup. The suspensions may comprise an in-soluble active compound of the invention or an acid addition or quaternary ammonium salt thereof in association with water, together with a suspending agent or flavouring agent.
Compositions for parenteral injection may be prepared from soluble salts, which may or may not be freeze-dried and which may be dissolved in water or an appropriate parenteral injection fluid.
In another aspect of the invention, the compounds may be mixed with other active anti-acid and anti-ulcer agents (excluding anticholinergic agents) for oral or, in appropriate cases, for parenteral use. :
The following Examples illustrate the preparation of piperidine derivatives of the present invention.
A solution of 2-methoxy-4-trifluoroacetylamino-5-chlorobenzoyl chloride ~17.4 g; 0.055 moles) dissolved in anhydrous ethyl methyl ketone (75 ml) was added little by little to another solution of 1-benzyl-4-ethyl-amino-piperidine ~10.9 g; 0.05 moles) and triethylamine (7.0 ml; 0.05 moles) in anhydrous ethyl methyl ketone (75 ml) at room temperature. On completion of the addition, the mixture was left at room temperature and stirred for 48 hours and then the mixture was concentrated under reduced pressure, poured into water and extracted with chloroform. The organic solution was dried (Na2SO4) and the solvent removed in vacuo. The residue was recrystallized from a mixture of methanol and diethyl ether to give N-ethyl-N-(l-benzyl-piperid-4-yl)-2-methoxy-4-trifluoroacetylamino-5-chlorobenzamide (17 g), m.p. 198-200C.
Also prepared in a similar manner were N-methyl-N-~l-benzylpiperid-4-yl)-2-methoxy-4-trifluoroacetylamino-5-chlorobenzamide, the hydrochloride of which melts at 251-252C, N-methyl-N-(l-benzylpiperid-4-yl)-2-methoxy-4-acetamido-5-chlorobenzamide, the fumarate of which melts at 199-201C (dec);
N-methyl-N-(l-benzylpiperid-4-yl)-2-methoxy-5-chlorobenzamide, the fumarate of which melts at 192-194C;
N-benzyl-N-(l-benzylpiperid-4-yl)-2-methoxy-5-chlorobenzamide, the fumarate of which melts at 196-197C;
N-methyl-N-(l-cyclohexa-1',4'-dienylmethylpiperid-4-yl)-2-methoxy-4-acetami-do-5-chlorobenzamide, m.p. 147-149C;
N-methyl-N-(l-cyclohexa-1',4'-dienylmethylpiperid-4-yl)-2-methoxy-4-trifluoro-acetylamino-5-chlorobenzamide, the hydrochloride of which melts at 210-212C;
and N-methyl-N-(l-cyclohexylmethylpiperid-4-yl)-2-methoxy-4-acetamido-5-chloro-benzamide, the hydrochloride of which melts at 264-266C.
The hydrochlorides mentioned above were obtained by addition of a saturated ethanolic solution of hydrogen chloride to a solution of the base in ethanol and further recrystallization.
In a similar manner, the fumarates mentioned above were obtained by adding fumaric acid in stoichiometric amount to a hot ethanolic solution of the piperidine base. The resulting hot solution was cooled and the fuma-rate crystallizes.
A solution of N-methyl-N-(l-benzylpiperid-4-yl)-2-methoxy-4-tri-fluoroacetylamino-5-chlorobenzamide (9.6 g; 0.02 moles)~ prepared as de-scribed in Example 1, in methanol (50 ml), water ~50 ml) and 8N sodium hy-droxide aqueous solution ~50 ml), was stirred for 48 hours at room tempera-ture. Then the mixture was diluted with water, extracted with chloroform, the organic solution dried (Na2SO4) and the solvent removed in vacuo. The residue (a viscous liquid) was treated with a saturated solution of ethanolic hydrogen chloride and N-methyl-N~ benzylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide hydrochloride (4.8 g), m.p. 259-260C (dec.), was obtained.
Also prepared in a similar manner was N-ethyl-N-(l-benzylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide hydrochloride~ m.p. 243-245C.
.
Triethylamine (2.78 ml; 0.02 moles) and ethyl chloroformate (1.9 ml; 0.02 moles) were added successively to a stirred suspension of 2-methoxy-4-amino-5-chlorobenzoic acid ~4.0 g; 0.02 moles) in anhydrous tetrahydro-furan (150 ml) whilst maintaining the temperature between -5 and -10C.
After stirring at this temperature for half an hour, a solution of l-cyclo-hexylmethyl-3-methyl-4-aminopiperidine (4.2 g; 0.02 moles) in anhydrous tetrahydrofuran (25 ml) was added and, after stirring for 1 hour at -5 to -10C, the temperature was allowed overnight to reach room temperature. The solvent of the mixture was removed in vacuo, the residue poured into water, extracted with chloroform and the organic layers washed with water. The chloroformic solution was dried (Na2SO4) and the solvent removed in vacuo to give N-(l-cyclohexylmethyl-3-methylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide (3.5 g), m.p. 173-176C.
Also prepared in a similar manner were N-(l-benzyl-3-methylpiperid-4-yl)-2-methoxy-4-amino-S-chlorobenzamide, the hydrochloride of which melts at 239-241C;
N-(l-benzyl-2,6-dimethylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide, the fumarate of which melts at 220-222C, and N-(l-cyclohexa-1^,4'-dienylmethyl-3-methylpiperid-4-yl)-2-methoxy-5-sulpho-~095~44 namidobenzamide, the fumarate of which melts at 207-209C (dec ).
Triethylamine (4.2 ml; 0.03 moles) and a solution of ethyl chloro-formate (2.85 ml; 0.03 moles) in anhydrous tetrahydrofuran (35 ml) were add-ed successively to a solution of 2-methoxy-4-amino-5-chlorobenzoic acid ~6.04 g; 0.03 moles) in N,N-dimethylformamide (225 ml) whilst main~aining the temperature at -10C. After stirring at this temperature for 2 hours, a solution of l-cyclohexylmethyl-4-methylaminopiperidine (6.15 g; 0.03 moles) in anhydrous tetrahydrofuran (35 ml) was added and the temperature was allowed overnight to reach room temperature. The mixture was poured into an aqueous solution of sodium bicarbonate, extracted with chloroform and the organic layers washed with water. The chloroformic solution was dried (Na2S04) and the solvent removed in vacuo to give a solid which was recrystallized from a mixture of ethanol and diethyl ether. N-Methyl-N-(l-cyclohexylmethylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide (9.6 g) was obtained.
The fumarate was prepared by the general procedure mentioned at the end of Example 1 and recrystallized from ethanol, m.p. 207~209C (dec.).
Also prepared in a similar manner were N-methyl-N-(l-benzylpiperid-4-yl)-2-methoxy-4-methylamino-5-chlorobenzamide, the fumarate of which melts at 214-216C (dec.);
N-methyl-N-(l-benzylpiperid-4-yl)-2-methoxy-4-aminobenzamide, the fumarate of which melts at 228-230C (dec.);
N-methyl-N-(l-benzylpiperid-4-yl)-2-methoxy-4-amino-5-bromobenzamide, the fumarate of which melts at 153-156C;
bis-[N-methyl-N-(l-benzylpiperid-4-yl)-2-ethoxy-4-amino-5-chlorobenzamide]
fumarate, m.p. 214-216C;
N-methyl-N-(l-benzylpiperid-4-yl)-2-allyloxy-4-amino-5-chlorobenzamide, the fumarate of which melts at 215-217C (dec.);
N-methyl-N-(l-benzylpiperid-4-yl)-2-methoxy-5-sulphamoylbenzamide, the fuma-rate of which melts at 189-191C (dec.~;
~0905(~4~
N-methyl-N-(l-benzylpiperid-4-yl)-2-methoxy-5-methylsulphonylbenzamide, the fumarate of which melts at 197-199C (dec.);
N-methyl-N-(l-p-methylbenzylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenza-mide, the fumarate of which melts at 228-230C (dec.);
N-methyl-N-(l-~-methylbenzylpiperid-4-yl)-2-methoxy-4-amino-5-bromobenzamide~
the fumarate of which melts at 220-222C (dec.);
N-methyl-N-(l-~-chlorobenzylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenza-mide, the fumarate of which melts at 235-237C (dec.);
N-methyl-N-(l-~-chlorobenzylpiperid-4-yl)-2-methoxy-4-amino-5-bromobenzamide, the fumarate of which melts at 230-232C (dec.);
N-methyl-N-[l-(l-phenylethyl)piperid-4-yl]-2-methoxy-4-amino-5-chlorobenza-mide, the fumarate of which melts a~ 207-209C (dec.);
N-methyl-N-[l-(l-phenylethyl)piperid-4-yl]-2-methoxy-4-amino-5-bromobenzamide, the fumarate of which melts at 201-203C (dec.);
N-methyl-N-(l-phenethylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide, the hydrochloride of which melts at 286-288C (dec.);
N-methyl-N-(l-diphenylmethylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide, m.p. 222-224C (dec.);
N-methyl-N-[1-(2-thienylmethyl)piperid-4-yl]-2-methoxy-4-amino-5-chlorobenza-mide, the hydrochloride of which melts at 269-271C (dec.);
N-methyl-N-(l-cyclohexa-1',4'-dienylmethylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide, the fumarate of which melts at 240-242C;
N-methyl-N-(l-cyclohexa-1',4'-dienylmethylpiperid-4-yl)-2-methoxy-4-amino-5-bromobenzamide, the fumarate of which melts at 233-235C (dec.);
N-methyl-N-(l-cyclohex-3'-enylmethylpiperid-4-yl)-2-methoxy-4-amino-5-chloro-benzamide, the fumarate of which melts at 195-197C ~dec.);
N-methyl-N-(l-cyclohexa-1',4'-dienylme~hylpiperid-4-yl)-2-methoxy-5-methyl-sulphonylbenzamide, the fumarate of which melts at 184-196C ~dec.)J and N-methyl-N-(l-benzylpiperid-4-yl)-2-methoxy-4,5-diaminobenzamide, the fumarate of which melts at 224-226C (dec.).
10950~4 A mixture of N-methyl-N-(l-benzylpiperid-4-yl)-2-methoxy-4-acet-amido-5-chlorobenzamide (12.9 g; 0.03 moles) [prepared as described in Ex-ample 1], concentrated hydrochloric acid ~10 ml) and wa~er ~30 ml) was boil-ed under reflux for 2 hours. The solution was concentrated in vacuo and the residue recrystallized from ethanol. N-Methyl-N-~l-benzylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide hydrochloride ~10.8 g) was obtained, m.p.
259 260C ~dec ) N,N'-Dicyclohexylcarbodiimide ~10.3 g; 0.05 moles) and 1-benzyl-4-methylaminopiperidine ~10.2 g; 0.05 moles) were added successively to a solu-tion of 2-methoxy-5-chlorobenzoic acid ~9.3 g; 0.05 moles) in methylene chloride ~250 ml). After stirring overnight at room temperature, the in-soluble N,N'-dicyclohexylurea was filtered off, the solution was washed with water, dried ~Na2SO4) and the solvent removed in vacuo to give an oil. It was salified with fumaric acid as described generally in Example 1 to give 10.3 g of N-methyl-N-~l-benzylpiperid-4-yl)-2-methoxy-5-chlorobenzamide fumarate, m.p. 192-194C.
To a solution of N-methyl-N-~l-benzylpiperid-4-yl)-2-methoxy-4-acetamido-5-chlorobenzamide ~4.3 g; 0.01 moles) [prepared as described in Example 1] in acetone ~100 ml) a solution of methyl iodide ~2.84 g; 0.02l moles) in acetone ~20 ml) was slowly added. The mixture was stirred at room temperature overnight, an additional amount of methyl iodide ~2.2 g; 0.016 moles) was added and the mixture ~shen boiled under reflux for 3 hours. The mixture was evaporated in vacuo and the residue triturated with diethyl ether to give 5.3 g of N-methyl-N-~l-benzylpiperid-4-yl)-2-methoxy-4-acet-amido-5-chlorobenzamide methyl iodide. After washing with acetone and re-crystallization from ethanol, this compound melted at 204C.
l~9S0~4 To a solution of N-methyl-N-(l-phenethylpiperid-4-yl)-2-methoxy-4-acetamido-5-chlorobenzamide (3.5 g; 0.0079 moles) [melting point 151-153C, prepared following the procedure of Example 1] in glacial acetic acid ~50 ml) a 30% hydrogen peroxide solution (3 ml) was added. The mixture was heated for 12 hours at a temperature between 70 and 80C, the solvent removed in vacuo and the residue dissolved in chloroform. This solution was washed with a saturated aqueous solution of sodium bicarbonate, dried (Na2S04) and the solvent removed in vacuo. The residue was crystallized from diethyl ether to give 2.6 g of the N-oxide of the benzamide starting mate-rial, m.p. 209-211C (dec.).
The following Examples illustrate pharmaceutical compositions ac-cording to the present invention.
100,000 tablets each containing 10 mg of N-(l-benzyl-3-methyl-piperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide hydrochloride were pre-pared from the following formulation:
N-(l-benzyl-3-methylpiperid-4-yl~-2-methoxy-4-amino-5-chlorobenzamide hydrochloride 1000 g microcrystalline cellulose 1800 g lactose spray dried 9020 g carboxymethyl starch 520 g sodium stearyl fumarate 80 g colloidal silicon dioxide 80 g Procedure:
All the powders were passed through a screen with an opening of 0.6 mm. They were then all mixed in a suitable mixer for 30 minutes and compressed into 125 mg tablet using 6 mm discs and flat bevelled punches.
The disintegration $ime of the tablets was abou~ 60 seconds.
~O9S0~4 EXAMPI,E 10 100,000 capsules each containing 10 mg of N~ benzyl-3-methyl-piperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide hydrochloride were pre-pared from the following formulation:
N-(l-benzyl-3-methylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide hydrochloride 1000 g lactose 8100 g sodium lauryl sulphate 370 g corn starch 8000 g alpine talc 530 g Procedure-The above ingredients were sieved through a 40 mesh sieve, then mixed in a suitable mixer and distributed into 100,000 gelatine capsules (180 mg).
10,000 suppositories each containing 15 mg of N-(l-benzyl-3-methyl-piperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide hydrochloride were pre-pared as follows:
N-(l-benzyl-3-methylpiperid-4-yl)-2-methoxy-4-amino-S-chlorobenzamide hydrochloride 150 g theobroma oil 19850 g Procedure:
The theobroma oil was melted and the active compound Suspended in it. The mixture was then poured into appropriate suppository moulds to make 2.0 g suppositories.
EXAMPLE_12 50,000 ampoules each containing 10 mg of N-(l-benzyl-3-methyl-piperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide hydrochloride were pre-pared from the following formulation:
N-~l-benzyl-3-methylpiperid-4-yl)-2-methoxy-4-109~04~
amino-5-chlorobenzamide hydrochloride 500 g sodium chloride 500 g water injectable grade q.s. lO0 litres Procedure:
The N-(l-benzyl-3-methylpiperid-4-yl)-2-methoxy-4-amino-5-chloro-benzamide hydrochloride and the sodium chloride were dissolved in approxi-mately 80 litres of water with slight heating. The solution was diluted with water to lO0 litres passed through a bacteria-retaining filter and filled into 2 ml glass ampoules in known manner.
The production of the injectable solution can take place under sterile conditions. It is also possible to work under normal conditions and then to heat-sterilize the filled ampoules.
l,000 bottles (capacity 150 ml) each containing 150 mg of N-~l-benzyl-3-methylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide hydrochlo-ride were prepared as follows:
N-(l-benzyl-3-methylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide hydrochloride 150 g sorbitol 70000 g sorbic acid 125 g citric acid 125 g distilled water q.s. 150 litres flavouring agent q.s.
Procedure:
The N~ benzyl-3-methylpiperid-4-yl)-2-methoxy-4-amino-5-chloro-benzamide hydrochloride and the sorbic acid were dissolved in 100 litres of water and then the sorbitol, citric acid and flavouring agent were added with stirring until dissolution. The mixture was diluted to 150 litres and divided amongst the bottles.
Similar compositions to those described in Examples 9 to 13 can ,~:
109.S044 be prepared having as the active ingredient piperidine derivatives of gen-eral formula I other than N-~l-benzyl-3-methylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide, for example other products conforming to that for-mula mentioned in Examples 1 to 4, 7 and 8.
According to a feature of the present invention, the compounds of general formula I are prepared by the process which comprises reacting a reactive derivative of a benzoic acid of the general formula:
Rl ~ ; C00~l IV
~wherein R, Rl and R2 are as hereinbefore defined) with a piperidine deri-vative of the general formula:
HN --~N-CH-W-R V
wherein the various symbols are as hereinbefore defined. The reactive deri-vative of the said benzoic acid may be a halide (preferably chloride), an alkyl ester (preferably methyl ester), an anhydride or a mixed anhydride.
The reaction is preferably carried out in the presence of an inert organic solvent, for example ethyl methyl ketone, benzene, toluene, chloro-form, tetrahydrofuran, N,N-dimethylformamide or dioxan, at a temperature between -5 and 120C.
Halides of the benzoic acids of general formula IV can be prepared 10 by reaction of the acid with thionyl chloride or a phosphorus halide in the presence of an inert organic solvent such as benzene, toluene or a haloge-nated hydrocarbon. Mixed anhydrides of the benzoic acids of general formula IV can be prepared by the reaction of the acid with, for example, an alkyl chloroformate in the presence of an organic nitrogen-containing base, e.g.
triethylamine, in an inert organic solvent, e.g. tetrahydrofuran, methylene chloride or N,N-dimethylformamide, and at a temperature between -20 and +25C. Esters and anhydrides of the benzoic acids of formula IV, which may be employed as starting materials in the aforementioned process, can be prepared from the benzoic acids by methods known per se.
The piperidine derivatives of general formula V wherein R7 is a hydrogen atom can be prepared by reduction of corresponding 4-piperidone oximes with lithium aluminium hydride in the presence of diethyl ether or tetrahydrofuran, or by reductive amination of corresponding 4-piperidones dissolved in an organic solvent, e.g. an alcohol containing 1 to 4 carbon atGms, in the presence of platinum or Raney nickel as catalyst. The piper~-~ dine derivatives of general formula V wherein R is a cyclohexadienyl group . _ ~
. ,, ~S0~4 can be prepared from the corresponding compounds of general formula V where-in R~ is a phenyl group by reduction with lithium in liquid ammonia or a lower alkylamine. The piperidine derivatives of general formula V wherein R is a lower alkyl or benzyl group can be prepared from corresponding N-acyl substituted compounds by reduction of the carbonyl group therein to methylene using lithium aluminium hydride. Other piperidine derivatives of general formula V can be prepared by methods known ~ se.
The piperidine derivatives of general formula I are also prepared, according to a further feature of the invention, by the direct reaction of a benzoic acid of general formula IV with a piperidine derivative of general formula V in the presence of an appropriate dehydrating agent. Such agents are silicon tetrachloride, a mono-, di- or trialkyl-silyl chloride, titanium tetrachloride, N,N'-dicyclohexyl-carbodiimide, thionyl chloride, sulphur trioxide in dimethyl sulphoxide, toluene-~-sulphonyl chloride, acetone dim-ethyl acetal or a polymeric dehydrating agent. The reaction is carried out in an inert organic solvent, e.g. methylene chloride, ace~one, pyridine, ethyl acetate or dioxan, at a temperature between 20 and 110C.
In the preparation of those compounds of general formula I, where-in the symbol(s) Rl and/or R2 represent(s) an amino group, by the aforemen-tioned processes it is sometimes advisable to use as starting material cor-responding compounds in which the amino group is protected by an acyl group, the acyl protecting group preferably being acetyl, chloroacetyl, trifluoro-acetyl or phthaloyl. After the reaction the N-acylated intermediate products are subjected to acid or alkaline hydrolysis to give the corresponding com-pound of general formula I in which Rl and/or R2 represent~s) an amino group.
Acid hydrolysis of the N-acylated intermediate compounds may be carried out by heating with dilute hydrochloric acid, preferably at the boiling point of the reaction mixture, while alkaline hydrolysis is preferably carried out at a temperature between 20 and 90C with sodium or potassium hydroxide in an aqueous-alcoholic solution.
1~95(1 44 The piperidine derivatives of general formula I have as their principal pharmacological properties the ability to antagonise the effects of dopamine or dopaminergic agents of endogenous or exogenous origin and to cause stimulation of serotoninergic mechanisms. In those circumstances where hemeostatic control is a balance between dopaminergic and serotoniner-gic mechanisms these two actions are synergistic and the precise contribu-tion of each one to the final biological response is difficult to determine.
As a group they have exhibited activities which may be considered beneficial in the treatment of obesity and a variety of gastrointestinal and cerebral malfunctions in mammals, including man. Their characteristic properties in experimental animals are antagonism of the effects of dopaminergic agents such as apomorphine, induction of catatonia, production of local anaesthesia, stimulation of gastrointestinal transit and induction of both spasmogenic and spasmolytic effects on smooth muscle according to the initial resting tone. Nevertheless, as within the series antidopaminergic, serotoninergic and local anaesthetic potency do not necessarily run in parallel, the clini-cal applications of the various derivatives may well be different. As a group, they may be useful as anorectic drugs in the treatment of obesity, and be effective in the treatment of nausea and vomiting of diverse origin such as that resulting from gastrointestinal disorders, congestive heart failure, post-operative conditions etc., as well as in the treatment of other gastrointestinal disorders such as dyspepsia, flatulance, bile regurgi-tation, hiatus nernia, peptic ulcer, reflux oesophagitis, gastritis, duode- `
nitis and cholelithiasis. They may also be useful in the treatment of a variety of conditions affecting the central nervous system such as acute and chronic psychosis, manic psychosis, schizophrenias, serious disturbances of behaviour and non-melancholic depressive states and migraine. Useful anorectic and antiemetic dosages of the more interesting compounds appear to lie between 5 and 100 mg. per day.
For therapeutic purposes the compounds of general formula I may be l~S044 employed in the form of biologically and pharmacologically-acceptable in-organic or organic acid addition salts such as sulphates, hydrohalides (e.g.
hydrochlorides), phosphates, lower alkanesulphonates, arylsulphonates, and salts of aliphatic or aromatic acids containing from 1 to 20 carbon atoms which may contain one or more dou~le bonds, or other functional groups such as hydroxy, lower alkoxy, amino or keto, e.g. fumarates.
They may also be used in the form of pharmacologically-acceptable quaternary ammonium salts such as those salts formed by reaction of the com-pounds of general formula I with lower alkyl halides (e.g. methyl iodide) or sulphates, or in the form of oxygenated derivatives in which oxygen is attached to the nitrogen atom of the piperidine nucleus, viz. the N-oxides.
The pharmacologically-acceptable acid addition salts, quaternary ammonium salts and N-oxides of the compounds of general formula I may be prepared by methods known per se.
Also included within the scope of the present invention are phar-maceutical compositions which comprise, as active ingredient, at least one compound of general formula I, or a pharmacologically-acceptable acid addi-tion or quaternary ammonium salt thereof or N-oxide thereof, in association with a pharmaceutically-acceptable carrier or diluent. Preferably the com-positions are made up in a form suitable for oral, topical, percutaneous orparenteral administration.
The pharmaceutically-acceptable carriers or diluents which are ad-mixed with the active compound) or compounds, or salts or N-oxides of such compounds, to form the compositions of this invention are well known ~ se and the actual excipients used depend inter alia on the intended method of administering the compositions. Compositions of this invention are prefer-ably adapted for administration ~ os. In this case, the compositions for oral adminstration may take the form of tablets, capsules, lozenges or effer-vescent granules or liquid preparations, such as mixtures, elixirs, syrups or suspensions, all containing one or more compounds of the invention; such lO9S~44 preparations may be made by methods well known in the art.
The diluents which may be used in the preparation of the composi-tions include those liquid and solid diluents which are compatible with the active ingredient, together with colouring or flavouring agents, if desired~
Tablets or capsules may conveniently contain between 1 and 200 mg, and pre-ferably from 2 to 100 mg, of active ingredient or the e~uivalent amount of an acid addition salt, quaternary ammonium derivative or N-oxide thereof.
The liquid compositions adapted for oral use may be in the form of solutions or suspensions. The solutions may be aqueous solutions of a soluble salt or other derivative of the active compound in association with, for example, sucrose to form a syrup. The suspensions may comprise an in-soluble active compound of the invention or an acid addition or quaternary ammonium salt thereof in association with water, together with a suspending agent or flavouring agent.
Compositions for parenteral injection may be prepared from soluble salts, which may or may not be freeze-dried and which may be dissolved in water or an appropriate parenteral injection fluid.
In another aspect of the invention, the compounds may be mixed with other active anti-acid and anti-ulcer agents (excluding anticholinergic agents) for oral or, in appropriate cases, for parenteral use. :
The following Examples illustrate the preparation of piperidine derivatives of the present invention.
A solution of 2-methoxy-4-trifluoroacetylamino-5-chlorobenzoyl chloride ~17.4 g; 0.055 moles) dissolved in anhydrous ethyl methyl ketone (75 ml) was added little by little to another solution of 1-benzyl-4-ethyl-amino-piperidine ~10.9 g; 0.05 moles) and triethylamine (7.0 ml; 0.05 moles) in anhydrous ethyl methyl ketone (75 ml) at room temperature. On completion of the addition, the mixture was left at room temperature and stirred for 48 hours and then the mixture was concentrated under reduced pressure, poured into water and extracted with chloroform. The organic solution was dried (Na2SO4) and the solvent removed in vacuo. The residue was recrystallized from a mixture of methanol and diethyl ether to give N-ethyl-N-(l-benzyl-piperid-4-yl)-2-methoxy-4-trifluoroacetylamino-5-chlorobenzamide (17 g), m.p. 198-200C.
Also prepared in a similar manner were N-methyl-N-~l-benzylpiperid-4-yl)-2-methoxy-4-trifluoroacetylamino-5-chlorobenzamide, the hydrochloride of which melts at 251-252C, N-methyl-N-(l-benzylpiperid-4-yl)-2-methoxy-4-acetamido-5-chlorobenzamide, the fumarate of which melts at 199-201C (dec);
N-methyl-N-(l-benzylpiperid-4-yl)-2-methoxy-5-chlorobenzamide, the fumarate of which melts at 192-194C;
N-benzyl-N-(l-benzylpiperid-4-yl)-2-methoxy-5-chlorobenzamide, the fumarate of which melts at 196-197C;
N-methyl-N-(l-cyclohexa-1',4'-dienylmethylpiperid-4-yl)-2-methoxy-4-acetami-do-5-chlorobenzamide, m.p. 147-149C;
N-methyl-N-(l-cyclohexa-1',4'-dienylmethylpiperid-4-yl)-2-methoxy-4-trifluoro-acetylamino-5-chlorobenzamide, the hydrochloride of which melts at 210-212C;
and N-methyl-N-(l-cyclohexylmethylpiperid-4-yl)-2-methoxy-4-acetamido-5-chloro-benzamide, the hydrochloride of which melts at 264-266C.
The hydrochlorides mentioned above were obtained by addition of a saturated ethanolic solution of hydrogen chloride to a solution of the base in ethanol and further recrystallization.
In a similar manner, the fumarates mentioned above were obtained by adding fumaric acid in stoichiometric amount to a hot ethanolic solution of the piperidine base. The resulting hot solution was cooled and the fuma-rate crystallizes.
A solution of N-methyl-N-(l-benzylpiperid-4-yl)-2-methoxy-4-tri-fluoroacetylamino-5-chlorobenzamide (9.6 g; 0.02 moles)~ prepared as de-scribed in Example 1, in methanol (50 ml), water ~50 ml) and 8N sodium hy-droxide aqueous solution ~50 ml), was stirred for 48 hours at room tempera-ture. Then the mixture was diluted with water, extracted with chloroform, the organic solution dried (Na2SO4) and the solvent removed in vacuo. The residue (a viscous liquid) was treated with a saturated solution of ethanolic hydrogen chloride and N-methyl-N~ benzylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide hydrochloride (4.8 g), m.p. 259-260C (dec.), was obtained.
Also prepared in a similar manner was N-ethyl-N-(l-benzylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide hydrochloride~ m.p. 243-245C.
.
Triethylamine (2.78 ml; 0.02 moles) and ethyl chloroformate (1.9 ml; 0.02 moles) were added successively to a stirred suspension of 2-methoxy-4-amino-5-chlorobenzoic acid ~4.0 g; 0.02 moles) in anhydrous tetrahydro-furan (150 ml) whilst maintaining the temperature between -5 and -10C.
After stirring at this temperature for half an hour, a solution of l-cyclo-hexylmethyl-3-methyl-4-aminopiperidine (4.2 g; 0.02 moles) in anhydrous tetrahydrofuran (25 ml) was added and, after stirring for 1 hour at -5 to -10C, the temperature was allowed overnight to reach room temperature. The solvent of the mixture was removed in vacuo, the residue poured into water, extracted with chloroform and the organic layers washed with water. The chloroformic solution was dried (Na2SO4) and the solvent removed in vacuo to give N-(l-cyclohexylmethyl-3-methylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide (3.5 g), m.p. 173-176C.
Also prepared in a similar manner were N-(l-benzyl-3-methylpiperid-4-yl)-2-methoxy-4-amino-S-chlorobenzamide, the hydrochloride of which melts at 239-241C;
N-(l-benzyl-2,6-dimethylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide, the fumarate of which melts at 220-222C, and N-(l-cyclohexa-1^,4'-dienylmethyl-3-methylpiperid-4-yl)-2-methoxy-5-sulpho-~095~44 namidobenzamide, the fumarate of which melts at 207-209C (dec ).
Triethylamine (4.2 ml; 0.03 moles) and a solution of ethyl chloro-formate (2.85 ml; 0.03 moles) in anhydrous tetrahydrofuran (35 ml) were add-ed successively to a solution of 2-methoxy-4-amino-5-chlorobenzoic acid ~6.04 g; 0.03 moles) in N,N-dimethylformamide (225 ml) whilst main~aining the temperature at -10C. After stirring at this temperature for 2 hours, a solution of l-cyclohexylmethyl-4-methylaminopiperidine (6.15 g; 0.03 moles) in anhydrous tetrahydrofuran (35 ml) was added and the temperature was allowed overnight to reach room temperature. The mixture was poured into an aqueous solution of sodium bicarbonate, extracted with chloroform and the organic layers washed with water. The chloroformic solution was dried (Na2S04) and the solvent removed in vacuo to give a solid which was recrystallized from a mixture of ethanol and diethyl ether. N-Methyl-N-(l-cyclohexylmethylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide (9.6 g) was obtained.
The fumarate was prepared by the general procedure mentioned at the end of Example 1 and recrystallized from ethanol, m.p. 207~209C (dec.).
Also prepared in a similar manner were N-methyl-N-(l-benzylpiperid-4-yl)-2-methoxy-4-methylamino-5-chlorobenzamide, the fumarate of which melts at 214-216C (dec.);
N-methyl-N-(l-benzylpiperid-4-yl)-2-methoxy-4-aminobenzamide, the fumarate of which melts at 228-230C (dec.);
N-methyl-N-(l-benzylpiperid-4-yl)-2-methoxy-4-amino-5-bromobenzamide, the fumarate of which melts at 153-156C;
bis-[N-methyl-N-(l-benzylpiperid-4-yl)-2-ethoxy-4-amino-5-chlorobenzamide]
fumarate, m.p. 214-216C;
N-methyl-N-(l-benzylpiperid-4-yl)-2-allyloxy-4-amino-5-chlorobenzamide, the fumarate of which melts at 215-217C (dec.);
N-methyl-N-(l-benzylpiperid-4-yl)-2-methoxy-5-sulphamoylbenzamide, the fuma-rate of which melts at 189-191C (dec.~;
~0905(~4~
N-methyl-N-(l-benzylpiperid-4-yl)-2-methoxy-5-methylsulphonylbenzamide, the fumarate of which melts at 197-199C (dec.);
N-methyl-N-(l-p-methylbenzylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenza-mide, the fumarate of which melts at 228-230C (dec.);
N-methyl-N-(l-~-methylbenzylpiperid-4-yl)-2-methoxy-4-amino-5-bromobenzamide~
the fumarate of which melts at 220-222C (dec.);
N-methyl-N-(l-~-chlorobenzylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenza-mide, the fumarate of which melts at 235-237C (dec.);
N-methyl-N-(l-~-chlorobenzylpiperid-4-yl)-2-methoxy-4-amino-5-bromobenzamide, the fumarate of which melts at 230-232C (dec.);
N-methyl-N-[l-(l-phenylethyl)piperid-4-yl]-2-methoxy-4-amino-5-chlorobenza-mide, the fumarate of which melts a~ 207-209C (dec.);
N-methyl-N-[l-(l-phenylethyl)piperid-4-yl]-2-methoxy-4-amino-5-bromobenzamide, the fumarate of which melts at 201-203C (dec.);
N-methyl-N-(l-phenethylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide, the hydrochloride of which melts at 286-288C (dec.);
N-methyl-N-(l-diphenylmethylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide, m.p. 222-224C (dec.);
N-methyl-N-[1-(2-thienylmethyl)piperid-4-yl]-2-methoxy-4-amino-5-chlorobenza-mide, the hydrochloride of which melts at 269-271C (dec.);
N-methyl-N-(l-cyclohexa-1',4'-dienylmethylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide, the fumarate of which melts at 240-242C;
N-methyl-N-(l-cyclohexa-1',4'-dienylmethylpiperid-4-yl)-2-methoxy-4-amino-5-bromobenzamide, the fumarate of which melts at 233-235C (dec.);
N-methyl-N-(l-cyclohex-3'-enylmethylpiperid-4-yl)-2-methoxy-4-amino-5-chloro-benzamide, the fumarate of which melts at 195-197C ~dec.);
N-methyl-N-(l-cyclohexa-1',4'-dienylme~hylpiperid-4-yl)-2-methoxy-5-methyl-sulphonylbenzamide, the fumarate of which melts at 184-196C ~dec.)J and N-methyl-N-(l-benzylpiperid-4-yl)-2-methoxy-4,5-diaminobenzamide, the fumarate of which melts at 224-226C (dec.).
10950~4 A mixture of N-methyl-N-(l-benzylpiperid-4-yl)-2-methoxy-4-acet-amido-5-chlorobenzamide (12.9 g; 0.03 moles) [prepared as described in Ex-ample 1], concentrated hydrochloric acid ~10 ml) and wa~er ~30 ml) was boil-ed under reflux for 2 hours. The solution was concentrated in vacuo and the residue recrystallized from ethanol. N-Methyl-N-~l-benzylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide hydrochloride ~10.8 g) was obtained, m.p.
259 260C ~dec ) N,N'-Dicyclohexylcarbodiimide ~10.3 g; 0.05 moles) and 1-benzyl-4-methylaminopiperidine ~10.2 g; 0.05 moles) were added successively to a solu-tion of 2-methoxy-5-chlorobenzoic acid ~9.3 g; 0.05 moles) in methylene chloride ~250 ml). After stirring overnight at room temperature, the in-soluble N,N'-dicyclohexylurea was filtered off, the solution was washed with water, dried ~Na2SO4) and the solvent removed in vacuo to give an oil. It was salified with fumaric acid as described generally in Example 1 to give 10.3 g of N-methyl-N-~l-benzylpiperid-4-yl)-2-methoxy-5-chlorobenzamide fumarate, m.p. 192-194C.
To a solution of N-methyl-N-~l-benzylpiperid-4-yl)-2-methoxy-4-acetamido-5-chlorobenzamide ~4.3 g; 0.01 moles) [prepared as described in Example 1] in acetone ~100 ml) a solution of methyl iodide ~2.84 g; 0.02l moles) in acetone ~20 ml) was slowly added. The mixture was stirred at room temperature overnight, an additional amount of methyl iodide ~2.2 g; 0.016 moles) was added and the mixture ~shen boiled under reflux for 3 hours. The mixture was evaporated in vacuo and the residue triturated with diethyl ether to give 5.3 g of N-methyl-N-~l-benzylpiperid-4-yl)-2-methoxy-4-acet-amido-5-chlorobenzamide methyl iodide. After washing with acetone and re-crystallization from ethanol, this compound melted at 204C.
l~9S0~4 To a solution of N-methyl-N-(l-phenethylpiperid-4-yl)-2-methoxy-4-acetamido-5-chlorobenzamide (3.5 g; 0.0079 moles) [melting point 151-153C, prepared following the procedure of Example 1] in glacial acetic acid ~50 ml) a 30% hydrogen peroxide solution (3 ml) was added. The mixture was heated for 12 hours at a temperature between 70 and 80C, the solvent removed in vacuo and the residue dissolved in chloroform. This solution was washed with a saturated aqueous solution of sodium bicarbonate, dried (Na2S04) and the solvent removed in vacuo. The residue was crystallized from diethyl ether to give 2.6 g of the N-oxide of the benzamide starting mate-rial, m.p. 209-211C (dec.).
The following Examples illustrate pharmaceutical compositions ac-cording to the present invention.
100,000 tablets each containing 10 mg of N-(l-benzyl-3-methyl-piperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide hydrochloride were pre-pared from the following formulation:
N-(l-benzyl-3-methylpiperid-4-yl~-2-methoxy-4-amino-5-chlorobenzamide hydrochloride 1000 g microcrystalline cellulose 1800 g lactose spray dried 9020 g carboxymethyl starch 520 g sodium stearyl fumarate 80 g colloidal silicon dioxide 80 g Procedure:
All the powders were passed through a screen with an opening of 0.6 mm. They were then all mixed in a suitable mixer for 30 minutes and compressed into 125 mg tablet using 6 mm discs and flat bevelled punches.
The disintegration $ime of the tablets was abou~ 60 seconds.
~O9S0~4 EXAMPI,E 10 100,000 capsules each containing 10 mg of N~ benzyl-3-methyl-piperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide hydrochloride were pre-pared from the following formulation:
N-(l-benzyl-3-methylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide hydrochloride 1000 g lactose 8100 g sodium lauryl sulphate 370 g corn starch 8000 g alpine talc 530 g Procedure-The above ingredients were sieved through a 40 mesh sieve, then mixed in a suitable mixer and distributed into 100,000 gelatine capsules (180 mg).
10,000 suppositories each containing 15 mg of N-(l-benzyl-3-methyl-piperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide hydrochloride were pre-pared as follows:
N-(l-benzyl-3-methylpiperid-4-yl)-2-methoxy-4-amino-S-chlorobenzamide hydrochloride 150 g theobroma oil 19850 g Procedure:
The theobroma oil was melted and the active compound Suspended in it. The mixture was then poured into appropriate suppository moulds to make 2.0 g suppositories.
EXAMPLE_12 50,000 ampoules each containing 10 mg of N-(l-benzyl-3-methyl-piperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide hydrochloride were pre-pared from the following formulation:
N-~l-benzyl-3-methylpiperid-4-yl)-2-methoxy-4-109~04~
amino-5-chlorobenzamide hydrochloride 500 g sodium chloride 500 g water injectable grade q.s. lO0 litres Procedure:
The N-(l-benzyl-3-methylpiperid-4-yl)-2-methoxy-4-amino-5-chloro-benzamide hydrochloride and the sodium chloride were dissolved in approxi-mately 80 litres of water with slight heating. The solution was diluted with water to lO0 litres passed through a bacteria-retaining filter and filled into 2 ml glass ampoules in known manner.
The production of the injectable solution can take place under sterile conditions. It is also possible to work under normal conditions and then to heat-sterilize the filled ampoules.
l,000 bottles (capacity 150 ml) each containing 150 mg of N-~l-benzyl-3-methylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide hydrochlo-ride were prepared as follows:
N-(l-benzyl-3-methylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide hydrochloride 150 g sorbitol 70000 g sorbic acid 125 g citric acid 125 g distilled water q.s. 150 litres flavouring agent q.s.
Procedure:
The N~ benzyl-3-methylpiperid-4-yl)-2-methoxy-4-amino-5-chloro-benzamide hydrochloride and the sorbic acid were dissolved in 100 litres of water and then the sorbitol, citric acid and flavouring agent were added with stirring until dissolution. The mixture was diluted to 150 litres and divided amongst the bottles.
Similar compositions to those described in Examples 9 to 13 can ,~:
109.S044 be prepared having as the active ingredient piperidine derivatives of gen-eral formula I other than N-~l-benzyl-3-methylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide, for example other products conforming to that for-mula mentioned in Examples 1 to 4, 7 and 8.
Claims (15)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. Process for the preparation of an N-piperid-4-yl benzamide compound of the general formula:
I
wherein R represents an alkoxy group containing 1 to 3 carbon atoms or an allyloxy group; R1 represents a hydrogen atom or an amino, alkylamino containing 1 to 3 carbon atoms or acylamino group containing 2 to 4 carbon atoms and wherein the alkyl group may be substituted with 1 to 3 halogen atoms; R2 represents a hydrogen or halogen atom or an amino, sulphamoyl or alkyl-sulphonyl group containing 1 to 3 carbon atoms, with the proviso that R1 and R2 do not both represent hydrogen atoms; R3 repre-sents a hydrogen atom, an alkyl group containing 1 to 3 carbon atoms, or a phenyl group; R4 represents a cyclohexyl, cyclo-hexenyl, cyclohexadienyl or thienyl group, or a phenyl group of the general formula:
wherein R8, R9 and R10 each represents a hydrogen or halogen atom or an alkyl group containing 1 to 3 carbon atoms; R5 repre-sents a hydrogen atom or an alkyl group containing 1 to 3 carbon atoms; R6 and R7 each represents a hydrogen atom, a benzyl group or an alkyl group containing 1 to 3 carbon atoms, with the proviso that R6 and R7 are not both hydrogen atoms when R5 represents a hydrogen atom; and W represents a single bond or an alkylene group containing 1 to 3 carbon atoms, or a pharmaceutically acceptable acid addition salt thereof, which process comprises (a) reacting a reactive derivative of a benzoic acid of the general formula:
IV
wherein R, R1 and R2 are as defined above, with a piperidine derivative of the general formula:
V
wherein the various symbols are as defined above; or (b) for the preparation of an N-piperid-4-yl benzamide of the general formula I wherein R1 and/or R2 represent(s) an amino group, re-acting a derivative of the benzoic acid of general formula IV
in which the amino group(s) is (or are) protected by an acyl group, with a piperidine derivative of formula V and thereafter removing the protecting acyl group(s) of the N-acylated inter-mediate product by acid or alkaline hydrolysis; and, if desired, converting the thus obtained compound into a pharmaceutically acceptable acid addition salt thereof.
I
wherein R represents an alkoxy group containing 1 to 3 carbon atoms or an allyloxy group; R1 represents a hydrogen atom or an amino, alkylamino containing 1 to 3 carbon atoms or acylamino group containing 2 to 4 carbon atoms and wherein the alkyl group may be substituted with 1 to 3 halogen atoms; R2 represents a hydrogen or halogen atom or an amino, sulphamoyl or alkyl-sulphonyl group containing 1 to 3 carbon atoms, with the proviso that R1 and R2 do not both represent hydrogen atoms; R3 repre-sents a hydrogen atom, an alkyl group containing 1 to 3 carbon atoms, or a phenyl group; R4 represents a cyclohexyl, cyclo-hexenyl, cyclohexadienyl or thienyl group, or a phenyl group of the general formula:
wherein R8, R9 and R10 each represents a hydrogen or halogen atom or an alkyl group containing 1 to 3 carbon atoms; R5 repre-sents a hydrogen atom or an alkyl group containing 1 to 3 carbon atoms; R6 and R7 each represents a hydrogen atom, a benzyl group or an alkyl group containing 1 to 3 carbon atoms, with the proviso that R6 and R7 are not both hydrogen atoms when R5 represents a hydrogen atom; and W represents a single bond or an alkylene group containing 1 to 3 carbon atoms, or a pharmaceutically acceptable acid addition salt thereof, which process comprises (a) reacting a reactive derivative of a benzoic acid of the general formula:
IV
wherein R, R1 and R2 are as defined above, with a piperidine derivative of the general formula:
V
wherein the various symbols are as defined above; or (b) for the preparation of an N-piperid-4-yl benzamide of the general formula I wherein R1 and/or R2 represent(s) an amino group, re-acting a derivative of the benzoic acid of general formula IV
in which the amino group(s) is (or are) protected by an acyl group, with a piperidine derivative of formula V and thereafter removing the protecting acyl group(s) of the N-acylated inter-mediate product by acid or alkaline hydrolysis; and, if desired, converting the thus obtained compound into a pharmaceutically acceptable acid addition salt thereof.
2. Process according to claim 1 in which a halide, alkyl ester, anhydride or a mixed anhydride of the benzoic acid IV is used.
3. Process according to claim 1 in which the reaction is carried out in the presence of an inert organic solvent at a temperature between -5° and 120°C.
4. Process according to claim 1, 2 or 3 wherein the benzoic acid of general formula IV and the piperidine derivative of general formula V are reacted in the presence of a dehydrating agent in an inert organic solvent at a temperature between 20°
and 110°C.
and 110°C.
5. An N-piperid-4-yl benzamide compound of the general formula I as defined in claim 1 or a pharmaceutically acceptable acid addition salt thereof, whenever prepared by the process of claim 1, 2 or 3, or by an obvious chemical equivalent thereof.
6. A process for the preparation of N-methyl-N-(1-benzylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide, in which 2-methoxy-4-amino-5-chlorobenzoic acid is reacted with 1-benzyl-4-methylaminopiperidine.
7. N-methyl-N-(1-benzylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide, whenever prepared by the process of claim 6, or by an obvious chemical equivalent thereof.
8. A process for the preparation of N-ethyl-N-(1-benzylpiperid-4-yl)-2-methoxy-4-amino-5-chloro-benzamide, in which 2-methoxy-4-amino-5-chlorobenzoic acid is reacted with 1-benzyl-4-ethylaminopiperidine.
9. N-ethyl-N-(1-benzylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide, whenever prepared by the process of claim 8, or by an obvious chemical equivalent thereof.
10. A process for the preparation of N-(1-cyclohexyl-methyl-3-methylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide, in which 2-methoxy-4-amino-5-chlorobenzoic acid is reacted with 1-cyclohexylmethyl-3-methyl-4-aminopiperidine.
11. N-(1-cyclohexylmethyl-3-methylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide, whenever prepared by the process of claim 10, or by an obvious chemical equivalent thereof.
12. A process for the preparation of N-(1-benzyl-3-methylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide, which comprises reacting 2-methoxy-4-amino-5-chlorobenzoic acid with 1-benzyl-3-methyl-4-aminopiperidine.
13. N-(1-benzyl-3-methylpiperid 4-yl)-2-methoxy-4-amino-5-chlorobenzamide, whenever prepared by the process of claim 12, or by an obvious chemical equivalent thereof.
14. A process for the preparation of N-(1-benzyl-2,6-dimethylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide, which comprises reacting 2-methoxy-4-amino-5-chlorobenzoic acid with 1-benzyl-2,6-dimethyl-4-aminopiperidine.
15. N-(1-benzyl-2,6-dimethylpiperid-4-yl)-2-methoxy-4-amino-5-chlorobenzamide, whenever prepared by the process of claim 14, or by an obvious chemical equivalent thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB45146/76A GB1586468A (en) | 1976-10-29 | 1976-10-29 | Piperidine derivatives |
| GB45146/76 | 1976-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1095044A true CA1095044A (en) | 1981-02-03 |
Family
ID=10436065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA289,825A Expired CA1095044A (en) | 1976-10-29 | 1977-10-28 | N-piperid-4-yl benzamide compounds |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4367232A (en) |
| JP (1) | JPS5377069A (en) |
| CA (1) | CA1095044A (en) |
| DE (1) | DE2747960A1 (en) |
| ES (2) | ES463633A1 (en) |
| FR (1) | FR2369263A1 (en) |
| GB (1) | GB1586468A (en) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5137896A (en) * | 1981-10-01 | 1992-08-11 | Janssen Pharmaceutica N.V. | N-(3-hydroxy-4-piperidinyl)benzamide derivatives |
| US4962115A (en) * | 1981-10-01 | 1990-10-09 | Janssen Pharmaceutica N.V. | Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives |
| US5057525A (en) * | 1981-10-01 | 1991-10-15 | Janssen Pharmaceutica N.V. | Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives |
| FR2534255B1 (en) * | 1982-10-11 | 1985-07-12 | Delalande Sa | NOVEL 4-AROYLAMINO PIPERIDINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC APPLICATION THEREOF |
| FR2546169B1 (en) * | 1983-05-20 | 1986-03-21 | Delalande Sa | N-OXIDES OF AMINOCYCLIC DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN THERAPEUTICS |
| GB8527052D0 (en) * | 1985-11-02 | 1985-12-04 | Beecham Group Plc | Compounds |
| FI95572C (en) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Process for the preparation of a medicament useful as a piperidine derivative or its pharmaceutical salt |
| GB9016580D0 (en) * | 1990-07-27 | 1990-09-12 | Ici Plc | Fungicides |
| GB9016581D0 (en) * | 1990-07-27 | 1990-09-12 | Ici Plc | Fungicides |
| TR27569A (en) * | 1992-01-24 | 1995-06-13 | Ici Plc | New fungicidal acylaminobenzamides, their preparation processes and their use in combating fungal infections in plants. |
| US5739135A (en) * | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| US5885983A (en) * | 1996-05-10 | 1999-03-23 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| US5827875A (en) * | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| US5883109A (en) * | 1996-07-24 | 1999-03-16 | Bristol-Myers Squibb Company | Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug |
| SE9902987D0 (en) * | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
| JP4664564B2 (en) | 2000-03-06 | 2011-04-06 | アカディア ファーマシューティカルズ，インコーポレーテッド | Nitrogen-containing cyclic compounds for the treatment of serotonin-related diseases |
| US20030176461A1 (en) * | 2000-04-20 | 2003-09-18 | Egle Ian R. | Aminopiperidines |
| GB0011838D0 (en) * | 2000-05-17 | 2000-07-05 | Astrazeneca Ab | Chemical compounds |
| US6803420B2 (en) * | 2001-05-01 | 2004-10-12 | Corium International | Two-phase, water-absorbent bioadhesive composition |
| NZ571695A (en) * | 2001-12-28 | 2010-02-26 | Acadia Pharm Inc | Spiroazacyclic compounds as monoamine receptor for modulating 5-HT2A receptor-mediated events |
| US7538222B2 (en) * | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
| CA2490397A1 (en) * | 2002-06-24 | 2003-12-31 | Acadia Pharmaceuticals Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
| US7253186B2 (en) * | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
| MY139563A (en) * | 2002-09-04 | 2009-10-30 | Bristol Myers Squibb Co | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| US7601740B2 (en) | 2003-01-16 | 2009-10-13 | Acadia Pharmaceuticals, Inc. | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
| WO2004069915A2 (en) * | 2003-02-10 | 2004-08-19 | Nippon Shokubai Co., Ltd. | Particulate water-absorbing agent |
| SE0301369D0 (en) * | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Chemical compounds |
| US20050261278A1 (en) * | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
| US7820695B2 (en) * | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
| SG161221A1 (en) * | 2004-09-27 | 2010-05-27 | Acadia Pharm Inc | Synthesis of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-næ-(4-(2- methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
| US7790899B2 (en) * | 2004-09-27 | 2010-09-07 | Acadia Pharmaceuticals, Inc. | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
| KR100904829B1 (en) * | 2004-12-20 | 2009-06-25 | 에프. 호프만-라 로슈 아게 | 4-aminopiperidine derivatives |
| AU2008228833B9 (en) | 2007-03-19 | 2013-10-24 | Acadia Pharmaceuticals Inc. | Combinations of 5-HT2A inverse agonists and antagonists with antipsychotics |
| CA2700331A1 (en) * | 2007-09-21 | 2009-03-26 | Acadia Pharmaceuticals, Inc. | Co-administration of pimavanserin with other agents |
| WO2017015272A1 (en) | 2015-07-20 | 2017-01-26 | Acadia Pharmaceuticals Inc. | Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c |
| US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
| WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
| EP3558311A1 (en) | 2016-12-20 | 2019-10-30 | Acadia Pharmaceuticals Inc. | Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis |
| EP3615028A1 (en) | 2017-04-28 | 2020-03-04 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
| WO2019046167A1 (en) | 2017-08-30 | 2019-03-07 | Acadia Pharmaceuticals Inc. | Formulations of pimavanserin |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2745837A (en) * | 1954-01-21 | 1956-05-15 | Schering Corp | Benzhydryl ethers of alkyl piperidinols |
| NL270803A (en) * | 1960-11-09 | |||
| US3342826A (en) * | 1964-01-13 | 1967-09-19 | Ile De France | Heterocyclic aminoalkyl benzamides |
| US3963745A (en) * | 1972-04-03 | 1976-06-15 | A. H. Robins Company, Incorporated | Method for controlling emesis with N-(1-substituted-3-pyrrolidinyl)benzamides and thiobenzamides |
| US3862139A (en) * | 1972-06-23 | 1975-01-21 | Delmar Chem | Heterocyclic benzamide compounds |
| CA1046066A (en) * | 1973-08-23 | 1979-01-09 | Tomio Muro | 1-(methylated piperidino (and pyrrolidin -1-yl)-3-(substituted phenoxy)-2-propanols |
| DE2513136C3 (en) | 1974-03-21 | 1981-04-30 | Anphar S.A., Madrid | N- (1-Benzylpiperid-4-yl) -benzamides, process for their preparation and pharmaceutical preparations containing them |
-
1976
- 1976-10-29 GB GB45146/76A patent/GB1586468A/en not_active Expired
-
1977
- 1977-10-26 DE DE19772747960 patent/DE2747960A1/en not_active Ceased
- 1977-10-27 US US05/845,958 patent/US4367232A/en not_active Expired - Lifetime
- 1977-10-28 ES ES463633A patent/ES463633A1/en not_active Expired
- 1977-10-28 FR FR7733339A patent/FR2369263A1/en active Granted
- 1977-10-28 ES ES463632A patent/ES463632A1/en not_active Expired
- 1977-10-28 CA CA289,825A patent/CA1095044A/en not_active Expired
- 1977-10-29 JP JP13018677A patent/JPS5377069A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DE2747960A1 (en) | 1978-05-11 |
| FR2369263A1 (en) | 1978-05-26 |
| ES463632A1 (en) | 1978-07-16 |
| FR2369263B1 (en) | 1980-06-13 |
| US4367232A (en) | 1983-01-04 |
| ES463633A1 (en) | 1978-07-01 |
| JPS5377069A (en) | 1978-07-08 |
| GB1586468A (en) | 1981-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1095044A (en) | N-piperid-4-yl benzamide compounds | |
| CA1094072A (en) | Cycloalkenyl derivatives of n-piperid-4-y1 benzamides | |
| GB1575310A (en) | Piperidine derivatives | |
| US4005208A (en) | N-Heterocyclic-9-xanthenylamines | |
| US5770735A (en) | Polycyclic amine compounds and their enantiomers, their method of preparation and pharmaceutical compositions in which they are present | |
| US3341538A (en) | Certain 2, 6-methano-3-benzazocines | |
| EP0035374B1 (en) | Piperidyl - urea, - thiourea and - guanidine derivatives, and intermediates therefor, processes for preparing them and pharmaceutical compositions containing the derivatives | |
| US4764612A (en) | 3-[3-[1-piperidinylmethyl]phenoxy]propanamine | |
| US4877780A (en) | Antiemetic N-substituted benzamides | |
| US3963745A (en) | Method for controlling emesis with N-(1-substituted-3-pyrrolidinyl)benzamides and thiobenzamides | |
| IE45833B1 (en) | Octahydro-quinolizinyl benzamide derivatives | |
| US5273983A (en) | Cyclohexylbenzamide derivatives, their preparations and their use as gastrointestinal stimulants | |
| US4207327A (en) | N-(4-Pyrazolidinyl)benzamides and their amino precursors | |
| NO770176L (en) | OXYGERATED N-ARYL DIAZACYCLES. | |
| US3117139A (en) | 4-aryl-1-carbamylalkyl-piperidines | |
| US4087428A (en) | N-(1-substituted-3-pyrrolidinyl)-4-quinoline carboxamides | |
| CA1086742A (en) | Preparation of 1-substituted-4-aroyl-4-hydroxy and -4- acyloxypiperidines | |
| CA1094075A (en) | Piperidine derivatives | |
| US4163789A (en) | Anti-psychotic (cycloalkenylalkylpiperidino) benzamides | |
| JPS6047255B2 (en) | Process for producing 2-amino-5-sulfamoyl-benzoic acid amide | |
| US3970661A (en) | 2-Amino, 5-carbamoyl pyridine compounds | |
| US4077954A (en) | N-(p-methylphenethyl)-4a-aryl-trans-decahydroisoquinolines | |
| GB1574419A (en) | Piperidine compounds | |
| NO782389L (en) | PIPERIDINOPROPANOLS. | |
| GB2207673A (en) | 2, 4, 5-tri-substituted benzamide derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |